Delgocitinib is first-in-class pan-Janus kinase inhibitor
Danish pharmaceutical company Leo Pharma announced in a press release positive results from the DELTA 3 open-label extension trial of delgocitinib cream.
Delgocitinib cream is an investigational potential first-in-class topical pan-Janus kinase inhibitor in development for treating moderate to severe chronic hand eczema in adults. The DELTA 3 trial is an open-label extension study of the phase 3 DELTA 1 and DELTA 2 studies.
The DELTA 3 trial evaluated the long-term safety of delgocitinib cream applied twice daily as needed for up to 36 weeks in adults with moderate to severe CHRONIC HAND ECZEMA. All participants of the DELTA 1 and DELTA 2 trials were offered enrollment in the DELTA 3 trial immediately after completion of the 16-week phase 3 studies. This included patients who received delgocitinib and those who received vehicle in the DELTA 1 and 2 trials.
The DELTA 3 study showed that delgocitinib cream was well tolerated after 36 weeks of treatment, consistent with previous safety results of the DELTA 1 and 2 trials. Furthermore, participants in the DELTA 3 trial maintained previous levels of symptom relief over the additional 36 weeks of treatment as they did during the first 16 weeks of the trial.
“It is encouraging to see the level of consistency that these long-term results show, in line with the previous positive results from the pivotal DELTA 1 and 2 trials. This condition can have a negative impact on patient quality of life, physical functioning, and ability to work, and there are currently no topical treatments specifically approved for moderate to severe chronic hand eczema," Kreesten Meldgaard Madsen, chief development officer at Leo Pharma, said in a press release.
"We will continue our work to investigate delgocitinib cream as a potential topical treatment for patients affected by this hard-to-treat disease.”
CHRONIC HAND ECZEMA is a type of atopic dermatitis that typically affects the backs of the hands and fingers and both sides of the wrists. Symptoms can include itching, dryness, stinging, burning, and pain in the affected areas. Some patients may experience more severe symptoms, such as scaling, fissures, and thickening of the skin on the hands and wrists.